On Monday, Tempus AI, Inc. (TEM) agreed to acquire Personalis, Inc. (PSNL), aiming to advance cancer monitoring through enhanced minimal residual disease (MRD) capabilities. Tempus AI shares erased early losses and recovered after an initial selloff tied to the company's acquisition of Personalis.

Tempus AI Targets $20 Billion MRD Market

The acquisition, valued at $1.5 billion, is set to expand Tempus' reach in the MRD market. Tempus claims it presents a $20 billion opportunity.

William Blair has a favorable view of the strategic fit and expects Personalis' growth and profitability trajectory to be meaningfully different inside of Tempus than it would have been as a standalone company. Both the clinical data and early commercial trajectory for NeXT Personal suggest Tempus is well-positioned to be a much larger player in the underpenetrated $20 billion TAM MRD market.

William Blair Sees Long-Term Growth But Flags Profitability Questions

The acquisition multiple is high at ~14 times 2027 consensus sales, though analyst Matt Larew wrote that the consensus likely understates Personalis' 2027 revenue outlook given recent MolDX approvals and Tempus' ability to further leverage its commercial infrastructure.

The other pressure point will be profitability given Personalis' clear loss-making position (consensus adjusted EBITDA of -$90 million for 2027) and Tempus's commitment to be EBITDA and FCF positive in 2027. Management argued that the timing of the acquisition is coincident with Personalis reaching an inflection point, with several years of commercial and reimbursement investment likely to yield enhanced ASPs and margins moving forward.

William Blair rates Tempus AI shares Market Perform. For multiple expansion to materialize, analyst Larew expects investors will want to see additional positive proof points on recent M&A contributing to numbers and more clarity on the growth profile and durability of the data business.

BNP Paribas Says Deal Could Increase Pressure On Natera

BNP Paribas wrote that while Tempus and Personalis already had a partnership in place, the combination may result in a stronger competitor for Natera Inc. (NTRA) in the MRD market. Analyst Navann Ty wrote that Natera maintains a defensible, leadership position in the space, with a solid pipeline of ongoing clinical trials. BNP Paribas maintains Neutral on Natera as the company continues to progress towards catalysts but views the current valuation as fair.

TEM Stock Price Activity: Tempus AI shares were up 1.96% at $49.36 at the time of publication on Tuesday, according to market data.